In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

UCB markets Watson's incontinence drug; terminated

Executive Summary

UCB SA's pharmaceutical division UCB Pharma SA has licensed European marketing rights to Watson Pharmaceuticals' Oxytrol, an oxybutynin transdermal system to treat urinary incontinence resulting from overactive bladder.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register